RNAi-based gene silencing mechanisms have emerged as indispensible tools for experimentally induced, sequence-specific inhibition of gene expression. The translation of these technologies for therapeutic applications has required the development of clinically feasible delivery strategies that facilitate the uptake of the siRNAs by specific cell type(s) and tissues. This feature review focuses on the progress made in the targeted delivery of siRNAs and the challenges encountered in the development of safe and effective therapeutic silencing agents.
|Original language||English (US)|
|Number of pages||7|
|State||Published - May 1 2010|
- Cell type-specific delivery
- Therapeutic gene silencing
ASJC Scopus subject areas
- Drug Discovery